As the second oral therapy approved by the U.S. Food and Drug Administration (FDA) for the treatment of Alzheimer’s disease during the past decade, ZUNVEYL demonstrates a potentially better safety ...
A simple digital health tool developed by Australian researchers could soon help predict the age of onset for early Alzheimer ...
Medical advances make pills to treat Alzheimer’s disease viable, though challenges remain in sharing gains globally ...
For decades, scientists have been trying to develop therapeutics for people living with Alzheimer’s disease, a progressive ...
A study has found cardiovascular conditions such as high blood pressure and diabetes, which are known to contribute to brain blood vessel damage in younger populations, not to be associated with an ...
Studies have long warned that blows to the head may raise the risk of neurodegenerative conditions. Now, scientists believe ...
POTOMAC, MD / ACCESSWIRE / January 8, 2025 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC Pharma" or the "Company") announced today that its ongoing Phase 2 trial for agitation in Alzheimer's disease ...
Getting a good night's sleep is a critical part of our daily biological cycle and is associated with improved brain function, ...
The New Brunswick, N.J., pharmaceutical giant said posdinemab has shown potential in targeting disease-associated phosphorylated tau in cerebrospinal fluid from treated Alzheimer's patients, and in ...
Johnson & Johnson (JNJ) announced that the FDA has granted Fast Track designation to its Posdinema, a monoclonal antibody ...
We have long suspected that music has restorative qualities, but Daniel Levitin is now providing rigorous evidence that it ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback